Trial Profile
The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jan 2021
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- 06 May 2019 Status changed from recruiting to completed.
- 24 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2019.
- 24 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2019.